Achieving lupus low-disease activity and remission states under belimumab in refractory systemic lupus erythematosus: time and organ involvement matter
Open Access
- 1 November 2020
- journal article
- letter
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 79 (11) , e148
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Lupus Low Disease Activity State (LLDAS) discriminates responders in the BLISS-52 and BLISS-76 phase III trials of belimumab in systemic lupus erythematosusAnnals of the Rheumatic Diseases, 2019
- Remission and Low Disease Activity Status (LDAS) protect lupus patients from damage occurrence: data from a multiethnic, multinational Latin American Lupus Cohort (GLADEL)Annals of the Rheumatic Diseases, 2017
- Remission in systemic lupus erythematosus: durable remission is rareAnnals of the Rheumatic Diseases, 2017
- A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS)Annals of the Rheumatic Diseases, 2017
- Definition and initial validation of a Lupus Low Disease Activity State (LLDAS)Annals of the Rheumatic Diseases, 2016
- Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosusArthritis & Rheumatism, 2012
- Novel evidence‐based systemic lupus erythematosus responder indexArthritis Care & Research, 2009
- Combined Oral Contraceptives in Women with Systemic Lupus ErythematosusNew England Journal of Medicine, 2005
- BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosusRheumatology, 2005
- The development and initial validation of the systemic lupus international collaborating clinics/American college of rheumatology damage index for systemic lupus erythematosusArthritis & Rheumatism, 1996